233 related articles for article (PubMed ID: 32060984)
1. Inhibition of copper chaperones sensitizes human and canine osteosarcoma cells to carboplatin chemotherapy.
Inkol JM; Poon AC; Mutsaers AJ
Vet Comp Oncol; 2020 Dec; 18(4):559-569. PubMed ID: 32060984
[TBL] [Abstract][Full Text] [Related]
2. Effects of the potassium-sparing diuretic amiloride on chemotherapy response in canine osteosarcoma cells.
Poon AC; Inkol JM; Luu AK; Mutsaers AJ
J Vet Intern Med; 2019 Mar; 33(2):800-811. PubMed ID: 30556178
[TBL] [Abstract][Full Text] [Related]
3. Biological activity of gemcitabine against canine osteosarcoma cell lines in vitro.
McMahon MB; Bear MD; Kulp SK; Pennell ML; London CA
Am J Vet Res; 2010 Jul; 71(7):799-808. PubMed ID: 20594083
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant carboplatin and gemcitabine combination chemotherapy postamputation in canine appendicular osteosarcoma.
McMahon M; Mathie T; Stingle N; Romansik E; Vail D; London C
J Vet Intern Med; 2011; 25(3):511-7. PubMed ID: 21488959
[TBL] [Abstract][Full Text] [Related]
5. The interaction between RUNX2 and core binding factor beta as a potential therapeutic target in canine osteosarcoma.
Alegre F; Ormonde AR; Godinez DR; Illendula A; Bushweller JH; Wittenburg LA
Vet Comp Oncol; 2020 Mar; 18(1):52-63. PubMed ID: 31381810
[TBL] [Abstract][Full Text] [Related]
6. The effects of taurolidine alone and in combination with doxorubicin or carboplatin in canine osteosarcoma in vitro.
Marley K; Helfand SC; Edris WA; Mata JE; Gitelman AI; Medlock J; Séguin B
BMC Vet Res; 2013 Jan; 9():15. PubMed ID: 23331343
[TBL] [Abstract][Full Text] [Related]
7. Combination therapy of canine osteosarcoma with canine bone marrow stem cells, bone morphogenetic protein and carboplatin in an in vivo model.
Rici REG; Will SEAL; Luna ACL; Melo LF; Santos AC; Rodrigues RF; Leandro RM; Maria DA
Vet Comp Oncol; 2018 Dec; 16(4):478-488. PubMed ID: 29781255
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant therapy with carboplatin and pamidronate for canine appendicular osteosarcoma.
Kozicki AR; Robat C; Chun R; Kurzman ID
Vet Comp Oncol; 2015 Sep; 13(3):229-36. PubMed ID: 23663234
[TBL] [Abstract][Full Text] [Related]
9. Pre-clinical evaluation of proteasome inhibitors for canine and human osteosarcoma.
Patatsos K; Shekhar TM; Hawkins CJ
Vet Comp Oncol; 2018 Dec; 16(4):544-553. PubMed ID: 29998615
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of P16 expression in canine appendicular osteosarcoma.
Murphy BG; Mok MY; York D; Rebhun R; Woolard KD; Hillman C; Dickinson P; Skorupski K
BMC Vet Res; 2017 Jun; 13(1):189. PubMed ID: 28633676
[TBL] [Abstract][Full Text] [Related]
11. Sorafenib and Doxorubicin Show Synergistic Effects in Human and Canine Osteosarcoma Cell Lines.
Yang YT; Yuzbasiyan-Gurkan V
Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012610
[TBL] [Abstract][Full Text] [Related]
12. Enrofloxacin enhances the effects of chemotherapy in canine osteosarcoma cells with mutant and wild-type p53.
York D; Withers SS; Watson KD; Seo KW; Rebhun RB
Vet Comp Oncol; 2017 Sep; 15(3):1087-1100. PubMed ID: 27333821
[TBL] [Abstract][Full Text] [Related]
13. STEALTH liposome-encapsulated cisplatin (SPI-77) versus carboplatin as adjuvant therapy for spontaneously arising osteosarcoma (OSA) in the dog: a randomized multicenter clinical trial.
Vail DM; Kurzman ID; Glawe PC; O'Brien MG; Chun R; Garrett LD; Obradovich JE; Fred RM; Khanna C; Colbern GT; Working PK
Cancer Chemother Pharmacol; 2002 Aug; 50(2):131-6. PubMed ID: 12172978
[TBL] [Abstract][Full Text] [Related]
14. Use of an artificial lymphatic system during carboplatin infusion to improve canine osteosarcoma blood flow and clinical response.
DiResta GR; Aiken SW; Brown HK; Bergman PJ; Hohenhaus A; Ehrhart EJ; Baer K; Healey JH
Ann Surg Oncol; 2007 Aug; 14(8):2411-21. PubMed ID: 17503157
[TBL] [Abstract][Full Text] [Related]
15. 17-AAG and Apoptosis, Autophagy, and Mitophagy in Canine Osteosarcoma Cell Lines.
Massimini M; Palmieri C; De Maria R; Romanucci M; Malatesta D; De Martinis M; Maniscalco L; Ciccarelli A; Ginaldi L; Buracco P; Bongiovanni L; Della Salda L
Vet Pathol; 2017 May; 54(3):405-412. PubMed ID: 28438108
[TBL] [Abstract][Full Text] [Related]
16. BMI1 is expressed in canine osteosarcoma and contributes to cell growth and chemotherapy resistance.
Shahi MH; York D; Gandour-Edwards R; Withers SS; Holt R; Rebhun RB
PLoS One; 2015; 10(6):e0131006. PubMed ID: 26110620
[TBL] [Abstract][Full Text] [Related]
17. Carboplatin versus alternating carboplatin and doxorubicin for the adjuvant treatment of canine appendicular osteosarcoma: a randomized, phase III trial.
Skorupski KA; Uhl JM; Szivek A; Allstadt Frazier SD; Rebhun RB; Rodriguez CO
Vet Comp Oncol; 2016 Mar; 14(1):81-7. PubMed ID: 24118677
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of toxicities from combined metronomic and maximal-tolerated dose chemotherapy in dogs with osteosarcoma.
Bracha S; Walshaw R; Danton T; Holland S; Ruaux C; Obradovich J
J Small Anim Pract; 2014 Jul; 55(7):369-74. PubMed ID: 24803081
[TBL] [Abstract][Full Text] [Related]
19. Impact of Toceranib/Piroxicam/Cyclophosphamide Maintenance Therapy on Outcome of Dogs with Appendicular Osteosarcoma following Amputation and Carboplatin Chemotherapy: A Multi-Institutional Study.
London CA; Gardner HL; Mathie T; Stingle N; Portela R; Pennell ML; Clifford CA; Rosenberg MP; Vail DM; Williams LE; Cronin KL; Wilson-Robles H; Borgatti A; Henry CJ; Bailey DB; Locke J; Northrup NC; Crawford-Jakubiak M; Gill VL; Klein MK; Ruslander DM; Thamm DH; Phillips B; Post G
PLoS One; 2015; 10(4):e0124889. PubMed ID: 25923466
[TBL] [Abstract][Full Text] [Related]
20. YM155 enhances the cytotoxic activity of etoposide against canine osteosarcoma cells.
Ong SM; Saeki K; Kok MK; Nakagawa T; Nishimura R
J Vet Med Sci; 2019 Aug; 81(8):1182-1190. PubMed ID: 31308291
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
